// App-Quantinova.ai

1883 : Treatment with histone deacetylase (HDAC) and BRAF inhibitors upregulates the expression of the plasma membrane Ca2+ pump, PMCA4b and alters intracellular Ca2+ handling in BRAF mutant melanoma cells

Researchers

Presenter

  • Luca Hegedus

Principal Investigators

  • Tamas Garay

  • Eszter Molnar

  • Karolina Varga

  • Rita Padanyi

  • Katalin Paszty

  • Balazs Hegedus

  • Mathias Wolf

  • Michael Grusch

  • Eniko Kallay

  • Agnes Enyedi

Medical Centers

  • Department of Pathophysiology and Allergy Research, Medical University of Vienna, Wien, Austria

  • Semmelweis University, Budapest, Hungary

  • Hungarian Academy of Sciences,, Hungary.

  • Division of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Wien, Austria

  • Institute of Cancer Research, Medical University of Vienna, Wien, Austria

  • Molecular Oncology Research Group of the Hungarian Academy of Sciences, Budapest, Hungary.

Locations

  • Austria

  • Hungary

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Melanoma

  • Solid malignancies

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

Drug/Treatment

  • Vorinostat

  • Valproic Acid

  • Valproate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved